Imagion Biosystems Appoints Dr Farideh Bischoff as Vice President of Clinical Research

Matthew Wygant Investor Updates, News

Cancer diagnostics industry veteran will lead first-in-human clinical trial program

Imagion Biosystems is pleased to announce the appointment of Farideh Bischoff, PhD, as the company’s Vice President of Clinical Research. Dr Bischoff will lead the clinical program for the company’s MagSense™ cancer detection technology, working to achieve regulatory approval as a diagnostic device for the early detection of malignant tumor cells.

Dr Bischoff adds a wealth of relevant experience in oncology product commercialisation to the leadership team at Imagion Biosystems. Her accomplishments include scientific development, regulatory submission and successful commercialisation of molecular diagnostics for Biocept. She has led numerous productive collaborative studies, including the NIFTY NIH Fetal Cell Study, composed of individuals from academic, pharmaceutical and biotech organisations.

She is widely recognised in the fields of rare cancer cell detection, molecular cytogenetics, diagnostic assay development and validation. Dr Bischoff holds a PhD from the University of Texas Graduate School of Biological Sciences, Houston. Her doctoral thesis led to the discovery of the p53 tumor suppressor gene and the emergence of a productive new avenue of global cancer research.

“We are very pleased to welcome Dr Bischoff to Imagion Biosystems as we progress toward first-in-human clinical studies,” said Imagion Executive Chairman and CEO Bob Proulx. “Dr Bischoff has the background and experience to help us move into the clinical setting, an area where she has worked for many years,” he added.

“I’m excited to be joining Imagion Biosystems as the company advances MagSense™ technology to the first-in-human clinical trial,” said Dr Bischoff. “The role at Imagion enables me to follow my passion for improving the lives of cancer patients. There is a large unmet medical need for earlier detection of malignant tumors.”

 

This information has been lodged with the Australian Securities Exchange and released via PR Newswire.